The effect of Endostar in inhibiting HIF-1 and promoting MHC class I expression on cancer cells, such as lung cancer cells, may counteract cancer immune evasion and thereby benefit cancer immunotherapy. This evidence concerns the gene HIF1A and lung cancer.